Gland Pharma Ltd

Gland Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gland Pharma Ltd

₹ 1,571 4.87%
21 May - close price
glandpharma.com BSE: 543245 NSE: GLAND
About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Key Points

Product Portfolio
The company is one of the largest and fastest-growing injectable-focused companies, providing 89+ product SKUs, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, across 15+ therapeutic areas. [1] [2]

The company launched 85 new molecules between FY22 and FY24, and introduced 12 new molecules, including Cetrorelix Acetate, Tranexamic Acid, Eribulin mesylate, Plerixafor, Nelarabine, etc., in the US market during H1 FY25. [3] [4]

Website BSE NSE
  • Market Cap ₹ 25,927 Cr.
  • Current Price ₹ 1,571
  • High / Low ₹ 2,221 / 1,200
  • Stock P/E 23.8
  • Book Value ₹ 592
  • Dividend Yield 1.27 %
  • ROCE 15.9 %
  • ROE 11.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 19.6%

Cons

  • The company has delivered a poor sales growth of 9.35% over past five years.
  • Company has a low return on equity of 11.6% over last 3 years.
  • Promoter holding has decreased over last 3 years: -6.17%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
1,103 857 1,048 926 785 884 1,011 1,098 1,175 1,012 1,063 1,011 1,030
755 587 753 642 616 625 664 728 742 718 699 620 636
Operating Profit 348 270 295 284 169 259 347 369 433 294 364 391 394
OPM % 32% 32% 28% 31% 22% 29% 34% 34% 37% 29% 34% 39% 38%
65 74 66 62 -18 35 41 43 47 48 58 65 44
Interest 2 1 2 3 2 2 1 1 5 1 0 18 3
Depreciation 31 35 37 38 38 39 40 40 43 41 42 44 43
Profit before tax 381 309 322 305 112 254 347 372 433 300 380 394 391
Tax % 25% 26% 26% 25% 29% 26% 26% 26% 26% 26% 26% 25% 26%
286 229 240 228 79 188 258 277 321 223 282 295 290
EPS in Rs 17.41 13.94 14.55 13.82 4.81 11.39 15.64 16.81 19.51 13.53 17.10 17.91 17.60
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
991 994 1,348 1,479 1,620 2,044 2,633 3,463 4,401 3,617 4,167 4,116
630 678 845 854 1,085 1,338 1,678 2,161 2,890 2,598 2,758 2,674
Operating Profit 361 316 502 625 535 706 955 1,302 1,511 1,019 1,410 1,443
OPM % 36% 32% 37% 42% 33% 35% 36% 38% 34% 28% 34% 35%
9 30 37 34 49 66 139 135 224 184 166 215
Interest 13 17 16 6 4 4 7 3 5 7 8 23
Depreciation 28 57 63 74 78 82 95 99 110 147 162 169
Profit before tax 327 272 459 578 502 686 993 1,335 1,619 1,048 1,405 1,466
Tax % 32% 23% 32% 28% 36% 34% 22% 25% 25% 26% 26% 26%
224 209 314 414 321 452 773 997 1,212 776 1,043 1,090
EPS in Rs 190.40 133.53 202.40 267.01 207.24 291.65 49.88 60.94 73.78 47.11 63.34 66.14
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 32% 27%
Compounded Sales Growth
10 Years: 15%
5 Years: 9%
3 Years: -2%
TTM: -1%
Compounded Profit Growth
10 Years: 18%
5 Years: 7%
3 Years: -3%
TTM: 4%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -20%
1 Year: -13%
Return on Equity
10 Years: 15%
5 Years: 14%
3 Years: 12%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 16 15 16 16 16 16 16 16 16 16 16
Reserves 822 1,379 1,662 2,074 2,395 2,847 3,631 5,887 7,142 7,937 8,979 9,739
176 166 117 6 6 5 5 5 5 4 4 5
277 197 292 378 512 655 435 588 671 815 542 661
Total Liabilities 1,287 1,758 2,086 2,474 2,928 3,523 4,086 6,496 7,834 8,773 9,541 10,422
460 649 788 872 843 929 968 954 1,502 1,571 1,694 1,745
CWIP 208 192 202 161 199 123 188 338 191 177 120 42
Investments 0 0 0 0 0 0 0 1 163 8 2,386 2,790
619 917 1,096 1,441 1,887 2,471 2,929 5,203 5,978 7,017 5,342 5,845
Total Assets 1,287 1,758 2,086 2,474 2,928 3,523 4,086 6,496 7,834 8,773 9,541 10,422

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
220 476 202 185 701 605 791 368 1,136 1,074
-12 -100 -359 -319 -761 -1,521 -1,007 1,211 -2,918 1,578
-93 -116 -4 -3 -7 1,238 35 15 -7 -340
Net Cash Flow 115 260 -160 -136 -67 322 -181 1,594 -1,789 2,312

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 62 62 95 103 107 90 83 71 89 87 103 101
Inventory Days 229 283 248 271 283 388 250 312 205 421 253 265
Days Payable 74 58 60 136 161 190 82 97 80 128 59 81
Cash Conversion Cycle 217 288 283 239 229 289 251 286 214 381 296 284
Working Capital Days 100 141 155 154 185 191 161 169 168 241 224 249
ROCE % 39% 22% 28% 30% 22% 27% 30% 28% 25% 15% 17% 16%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
57.87% 57.86% 57.86% 57.86% 57.86% 57.86% 57.86% 57.86% 51.83% 51.83% 51.83% 51.83%
9.41% 6.10% 4.67% 4.33% 2.80% 4.91% 4.05% 3.59% 6.88% 4.48% 5.04% 6.90%
17.36% 21.92% 23.13% 23.23% 23.38% 22.45% 24.17% 25.23% 32.83% 35.37% 34.80% 33.27%
15.35% 14.13% 14.35% 14.59% 15.97% 14.78% 13.93% 13.32% 8.46% 8.33% 8.33% 8.00%
No. of Shareholders 1,17,3391,27,8791,48,4691,50,5781,81,7471,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,788

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls